In this context, pharmacological inhibition of EAAT1 was sufficient to impair OCL formation by disrupting RANKL-mediated signaling, thereby targeting the tumor-altered metabolic pathways that drive osteoclastogenesis in the myeloma bone microenvironment. Here, SLC1A3 is linked to plasma cell myeloma.